portfolio
team
news
| Apr 09, 2010 |
Innovation, by Order of the Kremlin
The New York Times, New York, United States
Dr. Evgeny Zaytsev answers questions by Andrew Kramer, The New York Times correspondent, on the Russian initiative to build an "innovation city".
more >>
|
| Mar 09, 2010 |
Chimerix Initiates Phase 2 Study of CMX001 in Stem Cell Transplant Recipients Seropositive for Cytomegalovirus.
Chimerix, Inc., Durham, North Carolina
Chimerix announces a multi-center Phase 2 clinical trial designed to evaluate CMX001 in stem cell transplant recipients seropositive for cytomegalovirus (CMV).
more >>
|
| Jan 14, 2010 |
Pills Get Smart. Potential Encapsulated.
Economist, New York, United States
Article about the business potential of just announced licensing deal between Proteus Biomedical and Novartis.
more >>
|
| Sep 29, 2009 |
InteKrin Therapeutics Presents Positive Long Term INT131 Preclinical Cardiovascular Safety Data at the 45th Annual European Association for the Study of Diabetes Meeting
InteKrin Therapeutics, Los Altos, California
InteKrin announces positive safety data for for a new Type 2 Diabetes treatment.
more >>
|
| Sep 29, 2009 |
InteKrin Therapeutics Presents Positive INT131 Phase 2b Results at the 45th Annual European Association for the Study of Diabetes Meeting
InteKrin Therapeutics, Los Altos, California
InteKrin announces positive Phase IIb data for a new Type 2 Diabetes treatment with superior safety profile.
more >>
|
| Sep 20, 2009 |
Novartis chip to help ensure bitter pills are swallowed
Financial Times, London, UK
Article on possible Novartis collaboration with Proteus Biomedical to improve patient adherence.
more >>
|
| Aug 26, 2009 |
Asset Management Spinoff Helix Ventures Raising $150M Debut Fund
VentureWire, United States
Article by DowJones reporter Brian Gormley about formation of Helix Ventures.
more >>
|
| Aug 03, 2009 |
Take Two Digital Pills and Call Me in the Morning
The Wall Street Journal, United States
WSJ reporter Don Clark presents Proteus Biomedical’s intelligent medicine platform.
more >>
|
| Jul 15, 2009 |
BSI-201 Enters Phase 3 in Metastatic Triple Negative Breast Cancer
BiPar Sciences, Paris, France/South San Francisco, California
Recruitment Into Pivotal Phase 3 Study Initiated Just 2 Months After announcing positive Phase 2 Results.
more >>
|
| Jun 15, 2009 |
CMX001 a Broad Spectrum Antiviral Drug for the Treatment of Smallpox
Chimerix, Inc., Durham, North Carolina
Chimerix’ presentation at the 7th Annual Biodefense Vaccines and Therapeutics Meeting.
more >>
|
| May 30, 2009 |
New breast cancer drugs block cell repair enzyme
Reuters, United States
BiPar Sciences presents positive Phase II data at the annual meeting of the American Society of Clinical Oncology meeting.
more >>
|
| May 18, 2009 |
Emergency IND granted for the use of CMX001 to treat complications following smallpox vaccination
CDC, Atlanta, United States
CMX001, a drug developed by Chimerix, Inc. proves effective in an emergency case.
more >>
|
| May 12, 2009 |
Canaloplasty 2-year clinical results published
Ophthalmology Times, United States
iScience Interventional’s 2-year data confirm sustained eye pressure drop.
more >>
|
| Apr 15, 2009 |
BiPar Buyout Proves VC Model Can Work
The Wall Street Journal, United States
WSJ reporter Brian Gormley interviews Dr. Graham Crooke on the BiPar investment model.
more >>
|
| Apr 14, 2009 |
Sanofi-aventis to acquire BiPar Sciences, a US biopharmaceutical company
Sanofi-Aventis, Paris, France
Sanofi-aventis announces acquisition of BiPar for $500 million in a staged cash transaction.
more >>
|
| Jan 05, 2009 |
Chimerix completes Phase I study and initiates a Phase II multi-dose clinical trial for CMX001
Chimerix, Inc., Durham, North Carolina
Chimerix reports positive results of the Phase I clinical study in healthy volunteers.
more >>
|